 |
PDBsum entry 6yb7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Viral protein
|
PDB id
|
|
|
|
6yb7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Viral protein
|
|
|
Title:
|
|
Sars-cov-2 main protease with unliganded active site (2019-ncov, coronavirus disease 2019, covid-19).
|
|
Structure:
|
|
3c-like proteinase. Chain: a. Synonym: 3cl-pro,3clp,main protease,mpro,non-structural protein 5, nsp5,sars coronavirus main proteinase. Engineered: yes
|
|
Source:
|
|
Severe acute respiratory syndrome coronavirus 2. 2019-ncov, sars-cov-2. Organism_taxid: 2697049. Gene: rep, 1a-1b. Expressed in: escherichia coli. Expression_system_taxid: 562
|
|
Resolution:
|
|
|
1.25Å
|
R-factor:
|
0.144
|
R-free:
|
0.180
|
|
|
Authors:
|
|
C.D.Owen,P.Lukacik,C.M.Strain-Damerell,A.Douangamath,A.J.Powell, D.Fearon,J.Brandao-Neto,A.D.Crawshaw,D.Aragao,M.Williams,R.Flaig, D.R.Hall,K.E.Mcauley,M.Mazzorana,D.I.Stuart,F.Von Delft,M.A.Walsh
|
|
Key ref:
|
|
A.Douangamath
et al.
(2020).
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease.
Nat Commun,
11,
5047.
PubMed id:
|
|
|
Date:
|
|
|
16-Mar-20
|
Release date:
|
25-Mar-20
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
|
Nat Commun
11:5047
(2020)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease.
|
|
A.Douangamath,
D.Fearon,
P.Gehrtz,
T.Krojer,
P.Lukacik,
C.D.Owen,
E.Resnick,
C.Strain-Damerell,
A.Aimon,
P.Ábrányi-Balogh,
J.Brandão-Neto,
A.Carbery,
G.Davison,
A.Dias,
T.D.Downes,
L.Dunnett,
M.Fairhead,
J.D.Firth,
S.P.Jones,
A.Keeley,
G.M.Keserü,
H.F.Klein,
M.P.Martin,
M.E.M.Noble,
P.O'Brien,
A.Powell,
R.N.Reddi,
R.Skyner,
M.Snee,
M.J.Waring,
C.Wild,
N.London,
F.von Delft,
M.A.Walsh.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
COVID-19, caused by SARS-CoV-2, lacks effective therapeutics. Additionally, no
antiviral drugs or vaccines were developed against the closely related
coronavirus, SARS-CoV-1 or MERS-CoV, despite previous zoonotic outbreaks. To
identify starting points for such therapeutics, we performed a large-scale
screen of electrophile and non-covalent fragments through a combined mass
spectrometry and X-ray approach against the SARS-CoV-2 main protease, one of two
cysteine viral proteases essential for viral replication. Our crystallographic
screen identified 71 hits that span the entire active site, as well as 3 hits at
the dimer interface. These structures reveal routes to rapidly develop more
potent inhibitors through merging of covalent and non-covalent fragment hits;
one series of low-reactivity, tractable covalent fragments were progressed to
discover improved binders. These combined hits offer unprecedented structural
and reactivity information for on-going structure-based drug design against
SARS-CoV-2 main protease.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Links
